At a glance
- Originator 21st Century Therapeutics
- Developer 21st Century Therapeutics; Chengdu Xin Fanyu Biomedical; Sichuan New Phiaring Bio-medical Science
- Class Chemoprotectants; Isoxazoles; Radioprotectives; Small molecules
- Mechanism of Action Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Chemotherapy-induced damage; Radiation injuries
- No development reported Sepsis
Most Recent Events
- 14 Sep 2023 UTL-5g is still in preclinical trials for Chemotherapy-induced-damage (Prevention) in USA (21st Century Therapeutics, September 2023)
- 14 Sep 2023 UTL-5g is still in preclinical trials for Radiation-injuries (Prevention) in USA (21st Century Therapeutics, September 2023)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Sepsis in China